ArticleOncology and therapy2026
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to assess the cost-effectiveness of neoadjuvant nivolumab + platinum doublet chemotherapy (PDC) versus relevant comparators in the treatment of patients with non-metastatic (stage IB-IIIA), resectable, non-small cell lung cancer (NSCLC) in England.
methodsA four-state semi-Markov model (event-free survival, locoregional recurrence, distant metastasis, and death states) was developed. Key clinical inputs, including most transition probabilities and all health state utility inputs, were informed by data from the CheckMate-816 trial, which compared neoadjuvant nivolumab + PDC with neoadjuvant PDC. Neoadjuvant PDC, the trial comparator, is not typically used in England, so an indirect treatment comparison (ITC) estimated the relative efficacy of neoadjuvant nivolumab + PDC versus the relevant comparators. Comparators in the ITC and model were aligned with those suggested by the National Institute for Health and Care Excellence (NICE): neoadjuvant chemoradiotherapy, surgery alone, and surgery followed by adjuvant PDC. Costs were informed by standard UK sources. Cost and health outcomes were discounted by 3.5% per year.
resultsOver a lifetime time horizon, neoadjuvant nivolumab + PDC was dominant versus neoadjuvant chemoradiotherapy and adjuvant PDC, generating 0.26 and 0.7 incremental quality-adjusted life-years (QALYs) while reducing costs by £1674 and £240 per patient, respectively. Neoadjuvant nivolumab + PDC was more costly than surgery alone but was highly cost-effective; its estimated incremental cost-effectiveness ratio (ICER) was £2685 per QALY gained. Sensitivity and scenario analyses confirmed that these results are robust: only one of 10 scenarios tested yielded an ICER above £20,000 (the lower limit of the NICE reimbursement threshold).
conclusionNeoadjuvant nivolumab + PDC is a highly cost-effective treatment for nmNSCLC. The findings of this model supported positive reimbursement decisions for neoadjuvant nivolumab + PDC from NICE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.